Idexx Laboratories INC /de: insider trades · United States · SEC (Form 4)

About Idexx Laboratories INC /de

IDEXX Laboratories, Inc. (ticker: IDXX) is a U.S.-based company listed on the NASDAQ market in the United States. It is a global leader in veterinary diagnostics, practice software, and water microbiology testing. Founded in 1983 and headquartered in Westbrook, Maine, IDEXX has built a highly specialized healthcare franchise centered on companion animal medicine, recurring consumables, laboratory services, and software-enabled workflow solutions. The company’s positioning is anchored in innovation, high recurring revenue characteristics, and deep integration across instruments, reagents, reference lab services, and clinical software. IDEXX operates through three reportable segments: Companion Animal Group (CAG), Water, and Livestock, Poultry and Dairy (LPD). CAG is the core earnings engine and includes point-of-care analyzers for veterinary clinics, diagnostic tests, imaging-related solutions, reference laboratory services, and practice management software. Products and platforms such as Catalyst, SediVue, and IDEXX reference lab services are designed to help veterinarians make faster and more confident medical decisions while improving clinic efficiency. The Water segment offers microbiological testing solutions used to monitor water safety, and LPD serves animal protein production markets with diagnostics for cattle, poultry, and swine. From a competitive standpoint, IDEXX enjoys a strong market position thanks to its installed base, consumables-driven recurring revenue model, and broad product ecosystem. Management emphasizes that the combination of proprietary diagnostics, software integration, and lab services creates a differentiated customer proposition and meaningful switching costs. The company also has a broad international footprint: in 2025, about 36% of total revenue came from customers outside the United States, and IDEXX serves clients in more than 175 countries and territories. Recent developments have reinforced the growth story. In first-quarter 2026, IDEXX reported revenue of $1.141 billion, up 14% as reported and 11% organically, with growth led by the Companion Animal Group. The company has continued to expand its diagnostic portfolio, including new cancer and renal testing offerings, while also broadening the Catalyst platform. Management commentary in recent releases highlights continued gains in consumables usage, installed base expansion, and international momentum. For investors, IDEXX represents a high-quality healthcare technology business with secular tailwinds from pet health spending, diagnostic penetration, and recurring revenue growth, all while being listed on NASDAQ in the United States.